Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Development of Magnetic Resonance (MR) Simulation for Treatment Planning

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00314496
Recruitment Status : Completed
First Posted : April 14, 2006
Last Update Posted : February 25, 2016
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Brief Summary:

Retrospectively have access to MR images of patients to develop software that:

  1. segment images
  2. convert MR values to electron density and then
  3. entered into a dose calculation system

The project involves software development of data that is already available. No intervention is made at this point.

Condition or disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 10 participants
Time Perspective: Retrospective
Official Title: Development of MR Simulation for Treatment Planning
Study Start Date : September 2005
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patient with conform histological diagnosis of glioblastoma multiforme signed the consent forms and were willing to go for curative radiation treatment with temozolomide

Inclusion Criteria:

  • Subject 18 years of age and older

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00314496

Layout table for location information
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Layout table for investigator information
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta

Layout table for additonal information
Responsible Party: AHS Cancer Control Alberta Identifier: NCT00314496    
Other Study ID Numbers: EX-0004
First Posted: April 14, 2006    Key Record Dates
Last Update Posted: February 25, 2016
Last Verified: January 2012